Apalutamide Plus Intermittent Hormone Therapy (IHT) Versus IHT Alone in Prostate Cancer Patients With Biochemical Recurrence
Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 08 Aug 2017
At a glance
- Drugs Apalutamide (Primary) ; Leuprorelin
- Indications Adenocarcinoma; Prostate cancer
- Focus Therapeutic Use
- 02 Aug 2017 Planned primary completion date changed from 30 Jul 2021 to 31 Dec 2021.
- 02 Aug 2017 Planned initiation date changed from 1 Jul 2017 to 1 Dec 2017.
- 10 Jun 2017 Biomarkers information updated